Surrozen (SRZN) Stock Forecast & Price Target

Surrozen is attractive because its lead candidate SZN-8141 targets the retina with a differentiated bifunctional design that combines Wnt activation and VEGF inhibition, potentially addressing both vascular repair and leakage in diseases with substantial unmet need. The positive read-through from Merck’s pivotal Phase 2b/3 BRUNELLO results, including non-inferiority to ranibizumab at 52 weeks, lends external validation to Wnt biology and supports Surrozen’s strategy as SZN-8141 moves toward IND submission by the end of 3Q26 and a Phase 1b/2a DUET trial by year-end 2026. Fundamentally, the thesis is reinforced by strong preclinical synergy data, an improving intellectual property position after the PTAB denied institution of Merck’s challenge to the ’278 patent, and a model that now assigns a 20% probability of success to SZN-8141/8143 in DME.

Surrozen is challenged by a weak competitive position in retinal disease, where Vabysmo’s success highlights the advantage of combining anti-VEGF activity with Ang-2 inhibition on an established treatment backbone. Its lead Wnt agonist program has shown proof-of-concept in DME, but the higher incidence of PDR, vitreous hemorrhage, and AE-related discontinuations raises material safety concerns that remain unresolved. Until the magnitude, severity, timing, and mechanistic basis of these adverse events are clarified, the company’s clinical and regulatory risk profile remains elevated, limiting confidence in its long-term fundamentals.